Human Genome Sciences appoints Allan Baxter to board of directors
This article was originally published in Scrip
Human Genome Sciences has appointed Allan Baxter, previously senior vice-president of medicines development at GlaxoSmithKline (GSK), to its board of directors. Mr Baxter had a 30 year career at GSK, and created and led six of its centres of excellence for drug discovery, later taking on worldwide responsibility for its late-stage portfolio of investigational medicines from Phase II through to lifecycle management.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.